Hi Last week, MindBio enrolled the final patient in its landmark Phase 2B trial,trial testing MB22001 in patients with Major Depressive Disorder.READ MOREEven I have been surprised by the data from our trials as we slowly progress the drug to the nex...

Hi It's a marathon of clinical trials to get a new medicine approved and its worth it if MindBio's lead candidate MB22001 can prove more effective and without the side effects seen commonly in anti-depressant medications.To date, the trial outcomes h...

Hi MindBio Therapeutics (CNSX: MBIO) launches Booze AI to Investors in Silicon Valley.The World's First Voice Activated & AI Powered Blood Alcohol Estimator over a Smartphone goes Live.It was a surprising discovery with speech analysis in our cli...

Hi It's a marathon of clinical trials to get a new medicine approved and its worth it if MindBio's lead candidate MB22001 can prove more effective and without the side effects seen commonly in anti-depressant medications.READ MORETo date, the trial o...

Hi I am pleased to report that MindBio Therapeutics has completed the acquisition of Life AI Corp, a life sciences focused technology company that is developing predictive technologies for enhancing health and wellness. It's most progressive technolo...

Hi I am delighted to share a novel discovery in our clinical trials. Our engineers have developed a method to determine if a patient has dosed their medicine, simply by analysing their voice!The discovery has led to the announcement today of the acq...

MindBio Therapeutics Corp. Reports Six Month Sustained Antidepressant Response in Clinical Trials. 72% reduction in Depression Severity Recorded.Dear ,We are excited to share significant progress in our mission to transform mental health treatments....

Hi We are thrilled to share some significant progress from our ongoing Phase 2B clinical trial focused on advanced-stage cancer patients experiencing symptoms of anxiety, depression and existential distress. In this Phase 2B study, 40 participants ar...

Hi MindBio is pleased to report it has completed its 6-month milestone post treatment with MB22001 in a Phase 2A microdosing depression trial and will be releasing the data in the coming fortnight.Photo: Justin Hanka, MindBio CEO and Co-Founder insp...

Hi MindBio is pleased to report on long term stability data for its lead candidate drug MB22001. These stability findings, are an important part of our commercialisation journey, to produce medicines that can be stored and used safely for long perio...